Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

There’s no question that medications like semaglutide (Wegovy) and tirzepatide (Zepbound) have been making headlines lately. They’re two of the few injectable medications approved specifically for ...

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

While the WHO study saw reports of suicidal thoughts were slightly higher for semaglutide in particular, the warning applies for all GLP-1s, including Saxenda, Trulicity and Mounjaro. Semaglutide is ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has remained for users, what happens if they were to stay on the drug for years? Now ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug. CVS Caremark stopped covering Zepbound ...

Scientists discovered that people taking weight loss medications regained pounds weeks after they stopped taking the drugs. More than 1,000 people participated in a study and their lifestyle habits ...